

INFORMATION DISCLOSURE CITATION

MAR 04 2008

Docket No.: RLL-419US Serial No.: 10/596,528

Applicants: PALLE et al.

Filed: 6/15/2006

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A1	5,723,468	3/3/1998	Sabb et al.	514	262	
A2	6,028,076	2/22/2000	Hirota et al.	514	262	
A3	6,130,333	10/10/2000	Huang et al.	546	118	
A4	6,228,859	5/8/2001	Cavalla et al.	514	261	
A5	6,413,975	7/2/2002	Chasin et al.	514	261	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
B1	EP 0 544 445	6/2/1993	EPO	C07D	473/16	
B2	EP 1 221 444	7/10/2002	EPO	C07D	473/34	
B3	JP 2002 155002	5/28/2002	Japan	C07D	473/34	
B4	JP 2004 217582	8/5/2004	Japan	C07D	473/28	
B5	WO 02/05175	4/2/1902	PCT	C07D	473/06	
B6	WO 96/06045	9/7/1996	PCT	C07D	473/34	
B7	WO 99/11643	3/11/1999	PCT	C07D	471/04	
B8	WO 01/00507	1/4/2001	PCT	C07D	233/16	
B9	WO 01/02400	1/11/2001	PCT	C07D	473/34	
B10	WO 01/44260	6/21/2001	PCT	C07F	9/6561	
B11	WO 01/40688	7/12/2001	PCT	C07D	473/34	
B12	WO 03/002566	1/9/2003	PCT	C07D	473/16	
B13	WO 03/011864	2/13/2003	PCT	C07D	473/34	

EXAMINER

/Mark Berch/ (11/23/2009)

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-419US	Serial No.: 10/596,528
	Applicants: PALLE et al.	
	Filed: 6/15/2006	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Sutherland and Rall, "The Relation of Adenosine-3', 5'-Phosphate and Phosphorylase to the Actions of Catecholamines and Other Hormones", <i>Pharmacological Reviews</i> , <u>12</u> :265-299 (1960)
C2	Beavo and Reifsnyder, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", <i>Trends in Pharmacological Sciences</i> , <u>11</u> :150-155 (1990)
C3	Nicholson et al, "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", <i>Trends in Pharmacological Sciences</i> , <u>12</u> :19-27 (1991)
C4	Vergheese et al, "Anti-Neutrophil Activity of Cyclic Nucleotide Phosphodiesterase Inhibitors with Varying Cardiotonic Potencies", <i>Journal of Molecular Cell Cardiology</i> , <u>21</u> (suppl. II):S61 (1989)
C5	Torphy, 1988. Action of Mediators on Airway Smooth Muscle: Functional Antagonism as a Mechanism for Bronchodilator Drugs. In: O'Donnell and Persson, eds. <i>New Anti-Asthma Drugs</i> . Basel:Birkheuserverlag, 37-53
C6	Reimund et al, "Anti-TNF- α Properties of New 9-Benzyladenine Derivatives with Selective Phosphodiesterase-4-Inhibiting Properties", <i>Biochemical and Biophysical Research Communications</i> , <u>288</u> (2):427-434 (2001)
C7	Hedayatullah, "Les systèmes biphasiques. 3. Alkylation des purines en catalyse par transfert de phase (1a)", <i>Journal of Heterocyclic Chemistry</i> , <u>19</u> :249-251 (1982)
C8	Montgomery and Thomas, "On the Alkylation of Adenine (1)", <i>Journal of Heterocyclic Chemistry</i> , <u>1</u> (3):115-120 (1964)
C9	Carnaioni et al, "New substituted 9-alkylpurines as adenosine receptor ligands", <i>Bioorganic & Medicinal Chemistry</i> , <u>6</u> (5):523-533 (1998)
C10	Greene and Wutz, 1999. <i>Protective Groups in Organic Synthesis, Third Edition</i> . New York:Wiley Interscience Publications, 579-580
C11	Øgreid et al, "Evidence That Cyclic Nucleotides Activating Rabbit Muscle Protein Kinase I Interact with Both Types of cAMP Binding Sites Associated with the Enzyme," <i>The Journal of Biological Chemistry</i> , <u>258</u> (2):1041-1049 (1983)

EXAMINER	/Mark Berch/ (11/23/2009)	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		